+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Non-Hodgkin Lymphoma Treatment Market Research Report by Treatment, Cell Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 242 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 4968597
UP TO OFF until Dec 31st 2022
The Global Non-Hodgkin Lymphoma Treatment Market size was estimated at USD 7,073.93 million in 2021, USD 7,614.12 million in 2022, and is projected to grow at a CAGR of 7.81% to reach USD 11,109.57 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Non-Hodgkin Lymphoma Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Treatment, the market was studied across Chemotherapy, Immunotherapy, Radiation, Stem Cell Transplant, and Targeted Therapy.
  • Based on Cell Type, the market was studied across B-cell and T-cell.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Non-Hodgkin Lymphoma Treatment market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-Hodgkin Lymphoma Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-Hodgkin Lymphoma Treatment Market, including AbbVie Inc., Amgen, Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Kyowa Kirin Co., Ltd., Merck KGaA, Nordic Nanovector ASA, Novartis AG, Pfizer Inc., Pharmacyclics, LLC, and Sanofi SA.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Non-Hodgkin Lymphoma Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-Hodgkin Lymphoma Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-Hodgkin Lymphoma Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Non-Hodgkin Lymphoma Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Non-Hodgkin Lymphoma Treatment Market?
6. What is the market share of the leading vendors in the Global Non-Hodgkin Lymphoma Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Non-Hodgkin Lymphoma Treatment Market?
Frequently Asked Questions about the Global Non-Hodgkin Lymphoma Treatment Market

What is the estimated value of the Global Non-Hodgkin Lymphoma Treatment Market?

The Global Non-Hodgkin Lymphoma Treatment Market was estimated to be valued at $7073.93 Million in 2021.

What is the growth rate of the Global Non-Hodgkin Lymphoma Treatment Market?

The growth rate of the Global Non-Hodgkin Lymphoma Treatment Market is 7.8%, with an estimated value of $11109.57 Million by 2027.

What is the forecasted size of the Global Non-Hodgkin Lymphoma Treatment Market?

The Global Non-Hodgkin Lymphoma Treatment Market is estimated to be worth $11109.57 Million by 2027.

Who are the key companies in the Global Non-Hodgkin Lymphoma Treatment Market?

Key companies in the Global Non-Hodgkin Lymphoma Treatment Market include AbbVie Inc., Amgen, Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann, La Roche Ltd and Kyowa Kirin Co., Ltd..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
5.1.1.2. High unmet clinical needs and the launch of promising drugs
5.1.1.3. NHL patient prognosis and standard of care in front-line treatment regimens
5.1.2. Restraints
5.1.2.1. High cost of the treatment and certain side effects
5.1.3. Opportunities
5.1.3.1. Increase in research and development of therapeutic drugs against the disease
5.1.3.2. Rising investments from government and non-profit organizations
5.1.4. Challenges
5.1.4.1. Lack of awareness and limited resources
5.2. Cumulative Impact of COVID-19
6. Non-Hodgkin Lymphoma Treatment Market, by Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation
6.5. Stem Cell Transplant
6.6. Targeted Therapy
7. Non-Hodgkin Lymphoma Treatment Market, by Cell Type
7.1. Introduction
7.2. B-cell
7.3. T-cell
8. Americas Non-Hodgkin Lymphoma Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AbbVie Inc.
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Amgen, Inc.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. AstraZeneca PLC
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Bayer AG
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Bristol Myers Squibb Company
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Eli Lilly and Company
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. F. Hoffmann-La Roche Ltd
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. GlaxoSmithKline PLC
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Kyowa Kirin Co., Ltd.
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Merck KGaA
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Nordic Nanovector ASA
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Novartis AG
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Pfizer Inc.
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Pharmacyclics, LLC
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Sanofi SA
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2021 VS 2027 (%)
FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT, 2027
FIGURE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, 2018-2027 (USD MILLION)
FIGURE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
FIGURE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2021 VS 2027 (%)
FIGURE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY CELL TYPE, 2027
FIGURE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, 2018-2027 (USD MILLION)
FIGURE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, 2018-2027 (USD MILLION)
FIGURE 24. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 25. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 26. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 27. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 28. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 29. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 30. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 31. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 34. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 35. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 36. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 38. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 39. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 40. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 47. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 56. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 57. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 59. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 61. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 62. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 71. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 72. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 73. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 74. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 75. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 76. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 77. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 78. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 79. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2027 (USD MILLION)
TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, 2018-2027 (USD MILLION)
TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, BY REGION, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, 2018-2027 (USD MILLION)
TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2027 (USD MILLION)
TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2027 (USD MILLION)
TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, 2018-2027 (USD MILLION)
TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, BY REGION, 2018-2027 (USD MILLION)
TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, BY REGION, 2018-2027 (USD MILLION)
TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, 2018-2027 (USD MILLION)
TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, BY REGION, 2018-2027 (USD MILLION)
TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, BY REGION, 2018-2027 (USD MILLION)
TABLE 29. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 30. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 31. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 32. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 33. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 34. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 35. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 36. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 37. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 38. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 39. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 40. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 41. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 42. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 44. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 45. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 46. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 47. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 48. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 49. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 50. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 51. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 52. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 53. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 54. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 55. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 56. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 57. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 58. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 59. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 60. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 61. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 62. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 63. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 65. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 66. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 68. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 69. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 71. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 72. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 74. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 75. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 77. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 78. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 79. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 80. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 81. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 82. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 83. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 84. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 85. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 86. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 87. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 93. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 94. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 96. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 97. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 99. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 100. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 102. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 103. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 104. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 105. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 106. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 108. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 109. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 110. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 111. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 112. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 113. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 114. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 115. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 117. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 118. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 119. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 120. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 121. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 122. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 123. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 124. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 125. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 126. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 127. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 128. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 129. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 130. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 132. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 133. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 135. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 136. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 137. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 138. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 139. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 140. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 141. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 142. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 143. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 144. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 145. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 147. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 148. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 149. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 153. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 154. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2027 (USD MILLION)
TABLE 156. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 157. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 158. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 159. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RANKING, BY KEY PLAYER, 2021
TABLE 160. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
TABLE 161. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET MERGER & ACQUISITION
TABLE 162. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 163. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 164. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET INVESTMENT & FUNDING
TABLE 165. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 166. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Nordic Nanovector ASA
  • Novartis AG
  • Pfizer Inc.
  • Pharmacyclics, LLC
  • Sanofi SA

Methodology

Loading
LOADING...